Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Cardinal Health    CAH

CARDINAL HEALTH

(CAH)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cardinal Health, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 01:00pm EDT

Shareholders with $500,000 in losses or more are encouraged to contact the firm

Law Offices of Howard G. Smith reminds investors of the upcoming September 30, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Cardinal Health, Inc. (“Cardinal Health” or the “Company”) (NYSE: CAH) common stock between March 2, 2015 and May 2, 2018, inclusive (the “Class Period”).

Investors suffering losses on their Cardinal Health investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On August 2, 2017, Cardinal Health announced low earning for its fourth quarter and fiscal year 2017, along with lowering its earnings guidance for fiscal year 2018 due to “higher-than-planned write-offs for excess inventory” at Cordis Corp. (“Cordis”), which the Company had purchased in March 2015 from Johnson & Johnson (“J&J”).

On this news, Cardinal Health’s share price fell $6.34 per share, or over 8%, to close at $70.99 on August 2, 2017, thereby injuring investors.

Then, on May 3, 2018, the Company reported negative results for third quarter 2018 due to the “disappointing performance from [its] Cordis business.” Cardinal Health disclosed additional write-offs for millions of dollars of unsellable and expired heart stents and catheters stationed overseas.

On this news, Cardinal Health’s share price fell $13.85 per share, or over 21%, to close at $50.80 on May 3, 2018, thereby injuring investors

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the radio frequency identification inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis’s performance were never implemented across Cordis; (2) that Cordis’s existing global supply chain and inventory control systems were antiquated and ineffective, which were causing operational and inventory problems at Cordis; (3) that Cordis’s inventory and supply chain platforms were so deficient that the Company lacked visibility into customer demand and existing inventory levels, particularly with respect to products consigned to third-party vendors overseas; (4) that, as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; (5) that the Company failed to establish reserves, write off expired products, and subtract that inventory from the Company’s assets on its balance sheets; (6) that, as a result, the Company materially overstated Cordis’s inventory balances; (7) that, contrary to Defendants’ representations, Cordis was not “performing well” and its integration was not “on track,” “going incredibly well” or “largely on plan"; (8) that the Company struggled separating the Cordis business from J&J due to operational, manufacturing, and personnel deficiencies; and (9) that, to correct Cordis’s deficiencies, the Company would have to make substantial investments in Cordis’s IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.

If you purchased common stock of Cardinal Health during the Class Period you may move the Court no later than September 30, 2019 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARDINAL HEALTH
08:38aMEDICAL FLOOR MATS MARKET TO SHOW ST : DeRoyal Industries, Zimmer Biomet, Cardin..
AQ
08/16CARDINAL HEALTH : TBRC | Wound Care Devices Market Expected To Reach $18.28 Bill..
AQ
08/15CARDINAL HEALTH : ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Cardinal Health..
BU
08/15CARDINAL HEALTH : Glancy Prongay & Murray Reminds Investors of Looming Deadline ..
BU
08/14DEADLINE REMINDER : The Law Offices of Howard G. Smith Reminds Investors of Loom..
BU
08/14LEAD PLAINTIFF DEADLINE ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Su..
NE
08/13MARK MCLAUGHLIN : Qualcomm Taps Mark McLaughlin to Be New Board Chairman
DJ
08/09CARDINAL HEALTH : ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities C..
PR
08/08GLANCY PRONGAY & MURRAY LLP : Announces the Filing of a Securities Class Action ..
BU
08/08Health Care up Amid Deal Activity -- Health Care Roundup
DJ
More news
Financials (USD)
Sales 2020 152 B
EBIT 2020 2 233 M
Net income 2020 954 M
Debt 2020 4 434 M
Yield 2020 4,64%
P/E ratio 2020 13,4x
P/E ratio 2021 12,1x
EV / Sales2020 0,11x
EV / Sales2021 0,11x
Capitalization 12 960 M
Chart CARDINAL HEALTH
Duration : Period :
Cardinal Health Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARDINAL HEALTH
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 50,24  $
Last Close Price 43,48  $
Spread / Highest target 72,5%
Spread / Average Target 15,5%
Spread / Lowest Target 1,20%
EPS Revisions
Managers
NameTitle
Michael C. Kaufmann Chief Executive Officer & Director
Gregory B. Kenny Non-Executive chairman
Jorge M. Gomez Chief Financial Officer
Brian S. Rice Chief Information Officer & Executive VP
Calvin Ramarro Darden Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARDINAL HEALTH-2.51%12 960
WALGREENS BOOTS ALLIANCE-25.13%46 205
MCKESSON CORPORATION32.13%26 989
AMERISOURCEBERGEN17.94%18 281
SINOPHARM HOLDING CO LTD-17.48%10 262
SHANGHAI PHARMACEUTICALS HOLDING CO LTD4.47%6 597